TSPAN8 Antibody
- Known as:
- TSPAN8 Antibody
- Catalog number:
- XW-8169
- Product Quantity:
- 0.05 mg
- Category:
- -
- Supplier:
- Prosci
- Gene target:
- TSPAN8 Antibody
Related genes to: TSPAN8 Antibody
- Gene:
- TSPAN8 NIH gene
- Name:
- tetraspanin 8
- Previous symbol:
- TM4SF3
- Synonyms:
- CO-029
- Chromosome:
- 12q21.1
- Locus Type:
- gene with protein product
- Date approved:
- 1997-10-16
- Date modifiied:
- 2016-01-15
Related products to: TSPAN8 Antibody
Related articles to: TSPAN8 Antibody
- The extracellular matrix (ECM) plays a critical role in the tumor microenvironment (TME). However, the prognostic relevance of matrisome-related genes (MRGs) in bladder cancer (BLCA) remains poorly understood. This study aimed to establish a matrisome-related gene signature for prognostic stratification in bladder cancer and to further characterize its associations with tumor microenvironmental features and candidate compounds. - Source: PubMed
Publication date: 2026/04/20
Wu GongpingYu WeitaoYao DongnuanMa XuemingFan ChengweiHou JuanjuanRen XuezhaoTian Junqiang - KCNJ5-mutant aldosterone-producing adenomas (APAs) represent a primary cause of primary aldosteronism, leading to severe secondary hypertension. However, the adrenal cellular heterogeneity and microenvironmental landscape of KCNJ5-mutant APAs remain to be characterized. Using single-cell RNA sequencing and spatial transcriptomics, we analyzed three paired KCNJ5-mutant APAs and distal adrenal tissues (DATs), with experimental validation by immunohistochemistry and immunofluorescence. In DATs, we identified a previously unrecognized TSPAN8-positive zona glomerulosa (ZG) cell population. Pseudotime and functional enrichment analyses indicate that these cells represent an intermediate state between ZG and zona fasciculata (ZF). Within APAs, adrenocortical cells exhibited remarkable heterogeneity. The key enzyme mediating aldosterone synthesis, CYP11B2, was predominantly expressed in ZF-like cells, suggesting that targeting ZF-like cells may be critical for controlling aldosterone overproduction in APAs. Furthermore, CYP11B2-positive cells displayed two distinct functional states: Fate 1 (aldosterone-producing cells) specialized in mitochondrial metabolism and steroid hormone synthesis, while Fate 2 (tumor growth-promoting cells) participated in anti-apoptotic pathways that may drive APA cell accumulation. In contrast, CYP11B2-negative tumor cells demonstrated enhanced proliferative and differentiation potential, potentially playing a more active role in APA tumorigenesis. Notably, we discovered a unique subset of APA-associated macrophages (AAMs) within the tumor microenvironment. These AAMs were immunosuppressive and communicated with APA cells via the SPP1-(ITGAV/ITGB1) axis, likely promoting tumor proliferation. These findings provide novel insights into the cellular complexity of KCNJ5-mutant APAs, highlighting adrenal cortical cell plasticity and tumor-associated macrophages as critical determinants of APA pathogenesis. - Source: PubMed
Publication date: 2026/02/25
He FurongHu JinboZeng QinglianWang XiaoLi HongjiLi RuolinLi JiayuLi JunlongXiong YunjieYin JuanLiu YunyanPeng ChuanSong YingXu YongHuang WeiLi QifuMa LinqiangYang Shumin - Cancer-associated fibroblasts (CAFs) are a key cellular component of the tumor microenvironment (TME), which comprises distinct subtypes, each exhibiting unique and significant roles in cancer development. Senescent cancer-associated fibroblasts (senCAFs) are a newly identified subset of CAFs characterized by high expression of senescence-associated markers. Notably, senCAFs significantly promote tumor malignancy through the secretion of diverse senescence-associated secretory phenotype (SASP) factors, such as interleukin-6 (IL-6), interleukin-8 (IL-8), matrix metalloproteinases (MMPs), and transforming growth factor-β (TGF-β), thereby facilitating tumor cell proliferation, invasion, angiogenesis, immunosuppression, and resistance to cancer therapy. Consequently, targeting senCAFs-either through selective clearance of this cell subset or suppression of their SASP-represents a promising approach for cancer treatment. Emerging therapies include pharmacological inhibition of key SASP regulatory pathways (e.g., JAK/STAT3 and NF-κB) and antagonists targeting individual SASP components. Additionally, senolytic agents and therapies targeting senCAF-specific markers (e.g., TSPAN8) are being actively explored. Furthermore, immunotherapies, including CAR-T cells targeting senescence-associated surface proteins, provide intriguing avenues. These advances highlight senCAFs as attractive therapeutic targets and underscore the potential for integrating SASP inhibitors and senolytic agents into precision oncology paradigms. - Source: PubMed
Publication date: 2026/01/21
Feng YingyingZhi XiaochenXiao TingFeng Lin - Hepatocellular carcinoma (HCC) ranks among the leading causes of cancer-related mortality worldwide. Although HCC-selective diagnostics and treatments remain limited for late-stage disease, tumor-targeted radiopharmaceuticals offer a promising strategy to address this unmet need. Here, we identify tetraspanin-8 (TSPAN8) as a novel tumor-selective immuno-PET imaging target in HCC. TSPAN8 expression was analyzed in 4 HCC cell lines (Huh7, Hep3B, SNU182, and SNU449) and 1 hepatoblastoma cell line (HepG2) using Western blotting and flow cytometry. The binding kinetics of a monoclonal antibody (α-hTSPAN8) against human TSPAN8 were evaluated using enzyme-linked immunosorbent assay and biolayer interferometry. Clustered Regularly Interspaced Short Palindromic Repeats/Cas9-mediated gene editing was used to generate TSPAN8-knockout (TSPAN8) variants in Huh7 and Hep3B cells, validated through flow cytometry, immunofluorescence, and immunohistochemistry of xenograft tissues. Subcutaneous TSPAN8 and TSPAN8 xenografts were established in athymic NU/NU mice. For imaging studies, α-hTSPAN8 was conjugated with deferoxamine (DFO) and radiolabeled with Zr, a positron emitter. Tumor-specific uptake of [Zr]Zr-DFO-α-hTSPAN8 was evaluated by in vivo PET/CT imaging at 48, 72, and 144 h after injection, followed by an ex vivo biodistribution analysis. Huh7 and Hep3B cells exhibited high membrane TSPAN8 expression. The α-hTSPAN8 antibody demonstrated nanomolar affinity and specific binding to TSPAN8 cells. We synthesized both DFO-α-hTSPAN8 and [Zr]Zr-DFO-α-hTSPAN8 to greater than 98% purity and greater than 99% labeling efficiency, respectively, with the radioconjugate exhibiting excellent stability in human serum at 37 °C. In vivo PET/CT imaging and biodistribution studies showed significant and selective tracer accumulation in TSPAN8 tumors, with negligible uptake in TSPAN8 controls. Our findings establish TSPAN8 as a promising target for radiopharmaceutical development for the treatment of HCC. - Source: PubMed
Publication date: 2026/03/02
Sheehan-Klenk JuliaMakala HimaChung Joon-YongLee WoongheeBaidoo Kwamena ENambiar DivyaAlani NadaHewitt Stephen MUeda YukiOmiya SatoshiEscorcia Freddy E - Tumour-derived extracellular vesicles (TEVs) play a crucial role in cancer progression, metastasis and therapy resistance but their distinct profiles across different cancer stages and molecular subtypes remain underexplored. This study initially analysed TEVs from all CMS subtypes in colorectal cancer (CRC) cells and continued focusing on the epithelial (CMS2) and mesenchymal (CMS4) subtypes using six cell lines and clinical samples. Investigation of the cargo of vesicles secreted by the two subtypes revealed significant differences in mRNA, miRNA, and protein profiles between the two subtypes. Notably, CMS2 predominantly secreted smaller, Tetraspanin-8 (TSPAN8) enriched EVs, while CMS4 produced both larger and smaller EVs, enriched in TSPAN4. This underscores the complexity of vesicle heterogeneity between these subtypes. Additionally, we assessed miRNA profiles from plasma-derived bulk TEVs in CRC patients. Our integrative analysis identified a subtype-specific miRNA signature, indicating that TEVs from CMS2 and CMS4 cells can be detected in circulation and may serve as potential diagnostic tool for CRC. - Source: PubMed
Asif Paris JBorghuis Lauri Hvan Hooff Sander RGrootemaat Anita Evan Eijndhoven Monique A Jde Rooij JohanGroenewegen Nils JBoza Jennifer PerezKranenburg OnnoRinkes Inne H M BorelGómez-Martín CristinaPruijt Hans F Mvan der Wel Nicole NTorang ArezoBuffart Tineke EPegtel D MichielMedema Jan Paul